The Highwire with Del Bigtree - SCIENTIFIC FRAUD SETS ALZHEIMER’S SCIENCE BACK YEARS

Episode Date: November 5, 2024

A landmark Alzheimer’s paper from 2006, which has been the basis for treatment of the degenerative disease, has been retracted for containing fabricated images, making it the second most sighted medical paper to be rescinded. What does this mean for the multibillion dollar pharmaceutical industry and 132 other publications now under scrutiny?Become a supporter of this podcast: https://www.spreaker.com/podcast/the-highwire-with-del-bigtree--3620606/support.

When people hear about the word Alzheimer's, it's pretty scary as it should be. It's a devastating neurological disease. And it's right up there, I think if you ask anybody with cancer, these are the two things that no one wants to hear their loved one diagnosed with. And for people out there watching, you may think if you're younger, well, this is about older people. So I can tune out now, I'll catch the next segment. Not really, unfortunately.

Here's one of the recent headlines. More Americans are being diagnosed with early onset Alzheimer. How early? It says here, in the past few years, there have been a 200% increase in the numbers of Americans diagnosed in their 50s, 40s, and even in their 30s. And this is shocking. One of the things that has happened just over this past summer is there's this idea of what Alzheimer's is. The medical community tested a hypothesis, did some studies, and they said, aha, we found it. We found what causes Alzheimer's, and now it's time to build the pharmaceutical drugs to defeat this crippling disease, and we will win, just like we won against polio,

just like we won against all these other diseases. One problem, though, we have medical sleuths using new imaging technology, went back to the papers, the founding papers of the Alzheimer's theory. the dominant Alzheimer's theory of these amyloid beta plaques, these proteins, these misfolded proteins in the brains of people with Alzheimer's, they're saying that that is where the science pointed. They said people have these and we need to get these misfolded proteins out of their brains, therefore curing Alzheimer's. 2006 was the paper and it's been reviewed now and we have this. We have researchers, a neuroscience image sleuth, find signs of fabrication and scores of Alzheimer's

threatening a reigning theory of the disease. And this was the 2006 paper. They have these blots on a field is exactly what they are. And these blots are pictures of these misfolded protein bands. They found them in rats and they said, well, this must be it because they're misfolding in the brain. This is the beta amyloid protein. And when it folds, it disrupts the synapse.

It disrupts the communication in the brain. And we found it in rats. And we have these images. You can't deny these. images, but then when these sleuths looked at these images, they said, wait a minute, these images look like they're fabricated. What's going on here? And so those papers, that paper, is being retracted. What I mean by that, this is the headline right here. This is just in 2024 here, the recent one, researchers plan to retract landmark Alzheimer's paper containing doctored images. It goes on to say,

the study has been cited nearly 2,500 times and would be the second most cited. Most cited, paper ever to be retracted according to retraction watch. This is huge. Have you ever played Jenga where you pull out the block from the bottom and everything falls? The block from the bottom of Alzheimer's research, what we know about Alzheimer's, just was pulled out. Did you, did you know about that? Did the corporate media tell you about that? We have no idea what Alzheimer's is, but we have a large grouping of drugs that are pointed at Alzheimer's to look at, to look at at these amyloid beta plaques and get those out of the brain. Alzheimer shrinks the brain just turns out that these drugs focusing on those plaques

also shrink the brain. No one ever talked about that. But it's interesting because let's go to the next layer in this janga analogy. So the bottom layer just was pulled out. The next layer of research goes on and looks like this. This is science.org again, and they've been doing a lot of great work on this organization. Picture imperfect. This was just last month, 2024.

and it looks at Eliza Mislaia. He is a former head of the U.S. National Institute on Agings, Division of Neuroscience. And they chose this guy because of his extensive body of work with neuroscience. He's published an enormous amount of scientific literature on several of the subjects relating to neuroscience and Alzheimer specifically. So what did they find? This is kind of the next guy up on the ladder, right? This is the underpinning of this theory. Let's read.

They say in 2016, when the U.S. Congress unleashed a flood of new funding for Alzheimer's disease research, the National Institute on Aging tapped veteran brain researcher, Elizer Mislaia, as a key leader for the effort. He took the helm at the agency's Division of Neuroscience, whose budget $2.6 billion in the last fiscal year dwarfs the rest of NIA combined. Think about that. National Institute on Aging, what are they researching? Are they researching what exercise does to the brain? Are they researching what going on a walk? with your children in the woods, does the health of your brain? No, 2.6 billion towards drug development. That's how they stop you from aging, apparently. Let's go on this article and continue. As a leading federal ambassador to the research community and a chief advisor to NIA,

Director Richard Holt, Maslai would gain tremendous influence over the study and treatment of neurological conditions in the United States and beyond. It goes further. It says, after science brought initial concerns about Ms. Lai would gain tremendous influence over the study and treatment. lies work to their attention, a neuroscientist and forensic analysis specializing in scientific work who have previously worked with science produced a 300-page dossier revealing a steady stream of suspect images between 1997 and 2003 and 132 of his published research papers. Think about that. So it goes on to say even further, 132 of his research papers, not one, not two, 132 are under suspicion now for this gentleman that is at the head. head of this agency wielding billions of U.S. taxpayer dollars trying to find a cure for Alzheimer's.

Seems like it might be a little bit of a problem. Well, it goes further now because they talk about other neuroscientists here. The dossier challenges far more studies than the two cited in NIH's statement, including many that underpin the development testing of experimental drugs. It goes on to say, the enormity of apparent problem described in Maslaia's dossier stunned 11 neuroscientists who agreed to review it for science. Breathtaking, says neuroscientist Christian Haas of the Lugwood Maximilian University of Munich.

People will, of course, be shocked as I was. I was falling from a chair, basically. And here's another guy. He says, I'm floored, said Samuel Gandhi, a prominent neurologist at the Mount Sinai Alzheimer's Disease Research Center who was visibly shaken during a video interview, hundreds of images.

There had to have been ongoing manipulation for years. Let's look at Maslia's actual body of work here. So when other papers are cited, That's a big deal. And he has some of the king of cited papers in the Alzheimer's area. Look at nerve generation, world rank, world rank citation tally. Two and six, looking at amyloid, looking at the neuropathology, mouse models. These papers are some of the top cited papers by this guy, and they are now in question.

132 images of paper, 132 papers are in question. And why is this a big deal? So we have this idea that all these drug companies are developing drugs for it to get this amyloid beta out of the brain. This is now in question. But we don't hear any of this. Did you hear this on corporate media? Did they sound the alarm on this? No, they didn't.

In fact, all we get as the public are these grandstanding news reports of new drugs that are going to save the world like this. The new medication is offering hope. All eyes right now on this new drug. Tonight there's a new weapon in the fight against Alzheimer's disease. The first new FDA approved Alzheimer's drug in almost two decades. It's the first drug for Alzheimer's approved in nearly two decades. The FDA saying it is urgently needed to treat the devastating disease affecting more than six million Americans. The drug is a monoclonal antibody. It's called adiachanumab or adja helm, and it's designed to remove the clumps of beta amyloid proteins that accumulate.

in the brains of people with Alzheimer's. This treatment ushers in a new era in Alzheimer's treatments, going beyond just that symptom treatment to underlying biology. It has been granted conditional approval by the FDA after an accelerated approval process. The FDA granted approval with the agreement that biogen would conduct a new large clinical trial. The drug, of course, will be available to patients in the meantime. But if the trial fails to show... that it actually improved symptoms, the FDA could rescind its approval.

So the new drug that the FDA approved in June targets amyloid plaques very effectively. Unfortunately, the drug doesn't seem to have any clear effect on the progression of Alzheimer's disease. In order for a drug to be approved by the FDA, it has to show substantial evidence that the drug actually does work. It's a major, major breakthrough that has taken us from drugs that only deal with the symptoms to a drug that now can deal with one of the root causes. deal with one of the root causes of the disease. Possibly. Possibly.

So interesting with that, and if you're watching, this is where media literacy actually comes in. If you're watching those, or if you watch them originally in 2021 and 2023 when they approved these, you can see these drugs do a really good job in targeting this amyloid plaque, but it doesn't do much. There's Adjahelm, that was the first one in 2021. The Lequimbi in 2023 were approved. Oh my God, the first, the first one's in two-downs.

We're going to save the world. Well, what's interesting is in 2021, after they approved these for these fast track, three members of the FDA, three experts, resigned from an FDA committee over Alzheimer's drug approval. Think about how bad. What the heck did they see that made them jump ship? Remember during COVID when ASIP and the Verbat committee at the FDA was just rubber stamping, 12, 13 to zero, unanimous decisions to give COVID vaccines to 8.

infants and children, very, very low, minuscule risk of COVID, but given the vaccine, it's experimental, let's just get it out there. No one had a peep to say about that, but these drugs, three people, quit the committee, come on. So what did they see? Well, a new study was just published looking at the adverse event reporting system for these type of drugs, and maybe they saw this. This is Laquimbi and Aguim, those two drugs, the excess mortality in Alzheimer's patients on anti-amilibata monoclonal antibodies. What did they conclude? Are you ready? Conclusion. These findings suggest a three to four fold increase in mortality risk. It's going to kill you. These drugs will kill you three to four times faster than compared to untreated Alzheimer's disease population and a two to threefold

increase compared to the treated population in the clinical trials. If you're not falling off your chair on this, you should be. And let's talk about those. clinical trials for a second because remember this was the focus. These plaques in the brain, all pharmaceutical companies go. There is a product line you can make and there's market share to be had. The science supports it. Start developing drugs. And what happened was this this mad rush. And in that mad rush, informed consent was skipped over. The New York Times has just done a report. It's actually one of one of the authors is a Pulitzer Prize winning journalists. And it's, you got to give the hats off to when they write an actual good story. This was one of them. What drug makers

did not tell volunteers in the Alzheimer's trial, and even they are saying it just nakedly, this is what they write. Lequimbi and Kasunla, this was the other drug now. It's in 2024, it was approved. Seek to remove a misshapen protein called beta amyloid that forms plaques in the brains and patients with Alzheimer's. To a large extent, the drugs have succeeded, kind of a remarkable scientific achievement. Then it goes on to say this. It just lays it out there. Yet the drugs do not halt cognitive decline or reverse brain damage. La Quimbi slows the decline for roughly five months, while Kassunla achieves a slightly longer delay.

The evidence of their limited benefit is contributed to a growing realization that the dominant theory of Alzheimer's, that sticky bands of amyloid trigger a cascade of toxic events leading to the disease, is at best incomplete and perhaps simply wrong. So what they did in these clinical trials, these drug manufacturers, is there is a genetic variant called APOE4, and if you test for that, this genetic variant that people have

puts them at an extreme greater risk for developing Alzheimer's disease. And so these drug manufacturers really wanted people with that genetic variant in these trials and test this drug on. Well, it just so happens, it's widely known that if you have that genetic variant and you take these amyloid eliminating drugs,

you're at a huge risk for brain bleeds, microclots and death. That's well known in the literature. So when the people signed onto these trials, and you can read all about this in the New York Times story, it chronicles it in breathtaking, shocking, and sad detail. They signed onto these trials, and the informed consent said, we're going to genetically test you, but we're not going to tell you your own results for the test, because that might screw up the trials. So people walked in with these genetic variants and took the would put them at greater risk. And some of them had a really hard time, some of them died. And we don't know what happened to the rest of them because the drug companies won't release

the raw data. But that's what these drug companies were doing. So you can see at every level, you know, even if government officials have the right intention, even if a president has the right intention to say, we're going to defeat Alzheimer's, we're going to feed cancer. Underneath them, the capture regulatory agencies, the scientific fraud, the issues with the peer review process is a handicap at every level trying to get to the truth. And so here we are. We have no idea what Alzheimer's really is. The deck has been reshuffled and we're starting from square one again. So vitamins, minerals, physical activity, these don't have public relations departments, but we know physical activity and exercise has a great impact on the reduction of leading to

Alzheimer's. This is obvious. What else? Well, heavy drinking leads to Alzheimer's progression. And what else? Well, we have a doctor, Chris Exley, who's been on this show before. He's the world's leading researcher in aluminum. And he said at the time in 2017, looking at the brains of Alzheimer's patients, no aluminum, no Alzheimer's disease. This is what he said.

You came to a very strong conclusion that there was a, you know, strong connection between aluminum and... Well, I came to the conclusion that no aluminum, no Alzheimer's. No aluminum, no Alzheimer's. Wow. For that, being this first mover, this really novel idea, for being outside the box, he lost his lab, he's sitting on the sidelines as we speak right now,

wanting to get back into this fight. And this is his time. He should be there. People in the U.S. government, people and the National Institute of Aging should have brought him on in 2016 when the funding was there, but there's still hope he's still here and he's ready to go. So let's bring on some people that can really do some good work. Now, one of the things obviously we're doing on this show is we're deconstructing behind the headlines of these drugs because you're not going to see them. But unfortunately, it takes 10, sometimes 20 years to learn about the harms of these drugs, to learn about the ineffectiveness of these drugs. And by then, it's a lot of the it's already too late for a lot of people. Well, we have that opportunity right now with a new drug class.

And what am I talking about? These are the injectable weight loss drugs, the semi-glutides. You may know them by the names, Ozympic, Wagovi. Well, when you start seeing, we're in phase one right now of this. And the phase one is they can do no wrong, public relations push multimillion dollars,

and this is what it looks like. And notice the words here, we're gonna do a little, educational session. OZIPIC is a game changer. Remember that word. Here's how it works. Game changer. Let's see. It's such a game changer because this used to be a drug for diabetics, but then they use it off label and they found it can help people lose weight, so it shifted to a weight loss drug. It's such a game changer that people with diabetes that need insulin. Diabetes patients worry about insulin shortages as OZIMIC use skyrockets because they're going to

have to really rely on that at that point. But at, I seem to remember another game-changing drug. Just recently, we were told it was going to change the world. Oh, yeah, the COVID vaccine. COVID vaccine could be a drug industry game changer. 2020, there's Barron's. And so there's a couple other words here. Sometimes they go out of the analytical game changer, and they go right to the supernatural. They say it's a miracle. It's coming down from on high to save the world. And this is what they're talking about with this New York Times opinion piece. This is what a miracle drug looks like. And it costs only $5. to make. This is Ozimic. Well, again, miracle. I feel like we've been down this row before. What was a miracle? Oh, yeah, SSRIs, antidepressants. Antidepressants, once seen as a miracle

drug, now risks are becoming evident. And this is what happens in the second phase. Uh-oh, once it was a miracle and game changer. Now we have some risks, just a couple risks popping up here and there. But with Ozympic, the reason I'm focusing on this story right now, these semi-glutites is it's one thing for the pharmaceutical companies to maybe lie a little bit, to push their drug, have planted stories in the media because they're really doing bad right now and they need a pop of some good stories people are going to read. But it's another thing when governments see a drug as a game changer. And we're at a place right now. We've really never been and it's super dangerous. What do I mean by that? This is one of the headlines here.

why weight loss drugs like OZIMPIC are a game changer for the global economy. So one thing politicians, I would probably say one of the main things politicians want to do is reduce costs, tighten the budget, put more money in the pockets of the government so they can do more things. So when a drug comes along that they think or they're told can do that, things get really dicey. and this looks like what may be happening over in the UK. Here's their Secretary of Health. And he was just interviewed recently talking about these injectable weight loss drugs

and what his plan may be for them. Check it out. Some research that you are backing is a trial looking at how weight loss drugs could potentially get obese people back to work. Is medicating the population more really the way to do it, do you think? Look, I don't think that the answer to obesity is simply weight loss jabs,

but there is a lot of evidence to suggest already, and I'm really excited about the trial that we'll be doing with Lily. There's a lot of evidence already that these jabs, combined with changes to diet and exercise, can help people to reduce their weight, but also prevent cardiovascular disease and also diabetes, which is game-changing.

And for a lot of people, particularly people who are morbidly obese, they will tell you through bitter experience, even when they've tried to do the right thing, they find the challenge insurmountable. And these jabs can be a game changer on that. They're not the only solution, and I don't want to create a dependency culture. I also, by the way, you should say,

because there's been a lot of reaction to some of the things I've said this week, I'm also not interested in some dystopian future where I wander around kind of involuntarily jabbing unemployed people who are overweight. That is not the agenda. Well, first of all, basic public relations right here, when you're trying to really roll out a plan for the public to make it palatable,

you don't want to start backtracking in the very next sentence saying, I don't want this to be like some dystopian future where we're jabbing people indiscriminately. No, it'll probably be very focused these jabs on people. And so here's where it's incumbent for a leader of a country to step up and say, okay. You know, sometimes politicians say some crazy stuff every once in a while in a soundbite here or there. Sometimes, you know, you'll have a health secretary or, you know, here in the U.S. in the past, like someone like a Fauci go on TV and say, these jabs are going to stop the virus and you will never pass it on if you give it to somebody or something like that. But it's important for the leader of the country to come out and say, hey, look, it's not going to be a dystopian future. We're actually not going to try this. This is a crazy idea. We're just floating it.

This is what Kier Starrmer, the PM of the UK, should have came out in. said, but it sounded like this. Is it your view, like the health secretaries, that weight loss drugs could play a big role in solving worklessness and economic inactivity? I think these drugs could be very important for our economy and for health. Again, the story behind this is really interesting. Here's one of the biggest pharmaceutical businesses, pharma companies, that's decided now is the time to put the investment into our country. This is consistent. with our pitch, which is, you know, now is the time to invest in Britain,

doing their research here. This drug will be very helpful to people who want to lose weight, need to lose weight. Very important for the economy so that people can get back into work. Very important for the NHS, because, as I've said time and again, yes, we need more money for our NHS, but we've got to think differently. We've got to reduce the pressure on the NHS. So this will help in all of those areas.

We need to reduce the pressure on the NHS, and we need more money for the NHS. So we're going to jab obese, unemployed people and use them as a canary in the coal mine for pharmaceutical behavior modification. Do I have that right here, Starmor? It seems kind of crazy. You want to reduce the pressure on the NHS. How about rehiring all the nurses that you fired because they did not take the COVID jab? There's an idea. So there's where we are in the UK.

This is going to be a drug trial. You know, obviously they're not doing this in the entire population yet, but this is a drug trial. it looks like they may start to save money because it's such a game changer. So for the people in the UK, if this ever rolls out, this is the broadcast that you want to send to friends and family because nowhere in any of those did you hear we're going to try this, but this drug, these injectable drugs do have a couple things that people should watch out for if they take them or if they're being told to take them to get their unemployment benefits. And this is what we're going to do right now.

So in the FDA's own press release for these drugs, you have the start of, you have the start of these side effects, these things to look out for, and you can check them out right here. This was FDA approves new drug treatment for chronic weight management first since 2014. Wow, what a game changer. But it goes on to say in here, Wagovi also contains warnings for inflammation of the pancreas. Pancreatitis, gallbladder problem, gallstones. Those are super painful, I'm told. Low blood sugar, acute kidney injuries. damage to the eyes retina, increased heart rate, and suicidal behavior or thinking. What? Okay. Well, as we know, phase four of drug trials are the rollout on the general population. That is a fact. So there's kind of their little black box warning at the bottom of their press release for the FDA. But once the drug rolls out, then we really get to see the nuts and bolts of this. And these are the headlines we're seeing right now. These popular weight loss drugs linked to rare but severe stomach problems, study fines. A couple of people actually died from those. Ozympic may be linked to condition that causes blindness, but more research is needed.

Well, I hope someone jumps on that more research because it looks like the UK government might start jabbing people in the dystopian future. And those are my words. That's from the Health Secretary himself. So this is what we're looking at here. And I know these drugs are extremely popular. You go on TikTok, you go on Instagram. Everyone shares. these and it's not just you know people that have a really bad medical condition that desperately need to lose weight these are boutique drugs now these are kids are taking these drugs in fact the american academy of pediatrics themselves say that this should be the first top line therapy for kids 12 and older for weight loss medications you can see there 12 years and older

should really check this out and remember the american pediatrics are the same people that said kids should be able to consent to their own vaccines without parental consent or knowledge. They're also the ones in America that are fully behind the full transitioning of children without parental knowledge if need be. So that's American Academy of Pediatrics for you. So that's where we're at with Ozympic. We have a chance here to really put some science behind this miracle game-changing kind of media blitz that has everyone lost their minds on this.

So this is what we're talking about. So please share this with everybody if they're taking. taking this so they can look out for those side effects and talk to their doctor because I'm sure a lot of doctors are just giving this stuff out like candy, literally two kids, 12 and older.